Search

Your search keyword '"Seror, Olivier"' showing total 324 results

Search Constraints

Start Over You searched for: Author "Seror, Olivier" Remove constraint Author: "Seror, Olivier"
324 results on '"Seror, Olivier"'

Search Results

2. Patch-based field-of-view matching in multi-modal images for electroporation-based ablations

5. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

8. OS-110 ARMCENVIN: multibipolar radiofrequency ablation of HCC using intratumourous versus extratumourous “no-touch” techniques. French multicentric randomized controlled trial (NCT 01008657)

9. THU-459-YI Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma: a multicentric retrospective study

10. OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study

11. THU-487-YI Upfront multi-bipolar radiofrequency ablation for hepatocarcinoma in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence

13. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

14. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

17. Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma.

18. Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab

19. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma

24. Supplementary Figures 1 - 2 from Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

25. Supplementary Figure 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

26. Data from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

27. Supplementary Table 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

28. Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma

30. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress

32. Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization

34. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice

37. Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

41. Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion

43. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

44. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

45. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS

49. RADIOLOGICAL AND PATHOLOGICAL RESPONSE TO NEOADJUVANT NIVOLUMAB IN PATIENTS WITH BCLC A HCC TREATED BY CURATIVE PERCUTANEOUS IRREVERSIBLE ELECTROPORATION: PRELIMINARY REPORT FROM THE FRENCH MULTICENTRE PHASE 2 NIVOLEP TRIAL

Catalog

Books, media, physical & digital resources